-
公开(公告)号:US20230271968A1
公开(公告)日:2023-08-31
申请号:US18016164
申请日:2021-07-13
发明人: Cheung Ling Cheng , Yanping Zhao , Hongjun Wang , Bin Liu , Weiting Zhong , Huifen Xu , Chuangchuang Huang , Jing Li , Weina Liu
IPC分类号: C07D487/04 , A61P35/00
CPC分类号: C07D487/04 , A61P35/00
摘要: Disclosed is a compound of a general formula (I), which may be used for the treatment of ATR kinase-mediated diseases, for example, proliferative diseases such as cancer. Further disclosed are a preparation method for the compound of the general formula (I), a pharmaceutical composition, and use of the pharmaceutical composition for the treatment of ATR kinase-mediated diseases.
-
公开(公告)号:US11155819B2
公开(公告)日:2021-10-26
申请号:US16644977
申请日:2018-09-07
发明人: Yanping Zhao , Hongjun Wang , Yuanyuan Jiang , Weiting Zhong , Jianmei Pang , Gong Li , Xiang Li , Yixin He , Liying Zhou , Yanan Liu
摘要: The present invention relates to the field of biomedicine, particularly to double-stranded RNA molecules targeting CKIP-1 and uses thereof, particularly to use of the double-stranded RNA molecules for the treatment of inflammatory diseases such as arthritis, particularly rheumatoid arthritis.
-
公开(公告)号:US20230212160A1
公开(公告)日:2023-07-06
申请号:US17926533
申请日:2021-05-20
发明人: Yanping Zhao , Bin Liu , Yuanyuan Jiang , Weiting Zhong , Huifen Xu , Hongjun Wang , Li Mao , Jingtao Li , Honglei Zhang , Chuangchuang Huang , Jing .. Li , Jing Zhao , Weina Liu , Nana Tian , Liying Zhou , Yanan Liu
IPC分类号: C07D413/14 , C07D471/04 , C07D405/14 , A61P35/02 , A61P15/08 , A61P35/00
CPC分类号: C07D413/14 , A61P15/08 , A61P35/00 , A61P35/02 , C07D405/14 , C07D471/04
摘要: Provided are compounds represented by general formula (I), which can be used for treating ATR kinase-mediated diseases, such as proliferative diseases, such as cancer. Further provided are a pharmaceutical composition of the compound represented by general formula (I), a use thereof in treating ATR kinase-mediated diseases, and a preparation thereof.
-
公开(公告)号:US11130749B2
公开(公告)日:2021-09-28
申请号:US16344965
申请日:2018-06-29
发明人: Yanping Zhao , Hongjun Wang , Gong Li , Yuanyuan Jiang , Xiang Li , Bin Liu , Weiting Zhong , Kai Liu , Fajie Li , Liying Zhou , Yanan Liu
IPC分类号: C07D403/14 , C07D409/14 , C07D413/14 , C07D487/04 , C07D495/04 , C07D471/04 , C07D401/14 , C07D405/14 , C07D471/10 , C07D519/00 , C07D491/048 , C07D513/04 , C07D417/14 , C07D453/02 , C07F9/6558 , A61P37/00 , A61K31/416 , A61K31/506 , A61P29/00
摘要: The present invention relates to a Rho-associated protein kinase inhibitor of formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and a use of the same in preventing or treating a disease mediated by Rho-associated protein kinase (ROCK).
-
公开(公告)号:US11939578B2
公开(公告)日:2024-03-26
申请号:US17474396
申请日:2021-09-14
发明人: Yanping Zhao , Hongjun Wang , Yuanyuan Jiang , Weiting Zhong , Jianmei Pang , Gong Li , Xiang Li , Yixin He , Liying Zhou , Yanan Liu
CPC分类号: C12N15/113 , A61P19/02 , A61P19/08 , A61P29/00 , C12N15/85 , A61K48/00 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/334 , C12N2310/335
摘要: The present invention relates to the field of biomedicine, particularly to double-stranded RNA molecules targeting CKIP-1 and uses thereof, particularly to use of the double-stranded RNA molecules for the treatment of inflammatory diseases such as arthritis, particularly rheumatoid arthritis.
-
公开(公告)号:US20220378799A1
公开(公告)日:2022-12-01
申请号:US17616571
申请日:2020-06-05
发明人: Yanping Zhao , Hongjun Wang , Bin Liu , Yuanyuan Jiang , Weiting Zhong , Huifen Xu , Honglei Zhang , Chuangchuang Huang , Nana Tian , Jing Zhao , Jing Li , Weina Liu , Liying Zhou , Yanan Liu
IPC分类号: A61K31/5377 , C07D471/04 , C07D413/14 , A61P35/00
摘要: Compounds of general formula (A) can be used for treating ATR kinase-mediated diseases, for example, hyperplastic diseases such as cancers. Also provided are a pharmaceutical composition of the compounds of general formula (A), a use of the pharmaceutical composition for treating the ATR kinase-mediated diseases and a preparation method for the pharmaceutical composition.
-
-
-
-
-